Breaking News
Subscribe Now 0
Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 place See list
Close

Novo Nordisk A/S Class B (0QIU)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
816.00 -2.85    -0.35%
10:00:07 - Real-time Data. Currency in DKK ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  DK0060534915 
SEDOL:  BP6KMR9
  • Volume: 4,096
  • Bid/Ask: 801.50 / 834.20
  • Day's Range: 810.20 - 838.40
Novo Nordisk B 816.00 -2.85 -0.35%

0QIU Financial Summary

 
A brief financial summary of Novo Nordisk A/S Class B as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Novo Nordisk A/S reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was DKK 65,349 million compared to DKK 53,367 million a year ago. Net income was DKK 25,407 million compared to DKK 19,814 million a year ago. Basic earnings per share from continuing operations was DKK 5.7 compared to DKK 4.4 a year ago. Diluted earnings per share from continuing operations was DKK 5.68 compared to DKK 4.39 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

0QIU Income Statement

Gross margin TTM 84.53%
Operating margin TTM 45.96%
Net Profit margin TTM 34.84%
Return on Investment TTM 66.39%
 Total Revenue  Net Income
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Revenue 68060 65349 65863 58731
Gross Profit 57786 55433 55849 49018
Operating Income 31634 31846 28180 26913
Net Income 20050 25407 21963 22478

0QIU Balance Sheet

Quick Ratio MRQ 0.67
Current Ratio MRQ 0.94
LT Debt to Equity MRQ 45.86%
Total Debt to Equity MRQ 50.71%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Total Assets 369383 298921 314486 300101
Total Liabilities 256861 200010 207925 207110
Total Equity 112522 98911 106561 92991

0QIU Cash Flow Statement

Cash Flow/Share TTM 26
Revenue/Share TTM 58.17
Operating Cash Flow  26.88%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 50503 14314 9551 40966
Cash From Investing Activities -20731 3956 -14717 -13243
Cash From Financing Activities 16683 -26382 -10116 -19832
Net Change in Cash 46497 -8068 -15491 8309
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NOVOb Comments

Write your thoughts about Novo Nordisk L
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email